FDA approves Immunovaccine DPX-Survivac study

The FDA has reviewed and cleared Immunovaccine’s (TSX:IMV) investigational new drug application for a Phase 1/2 clinical study with DPX-Survivac, a therapeutic cancer vaccine, to be tested in patients with ovarian cancer. The DPX-Survivac vaccine candidate uses antigens from survivin (in-licensed from Merck KGaA), which are formulated in the DepoVax vaccine delivery platform. DepoVax is [...]

Synta readying two key lung cancer trials

Synta Pharmaceuticals (NASDAQ:SNTA) is gearing up to begin two key clinical trials in non-small cell lung cancer (NSCLC) with its two novel compounds – ganetespib and elesclomol – that are being closely watched by potential Big Pharma partners. “Both are differentiated from anything else that’s out there,” CEO Dr. Safi Bahcall says in an exclusive [...]

Immunovaccine reports positive interim data

Immunovaccine (TSX:IMV) has reported interim immunogenicity results for a Phase I clinical trial of its therapeutic vaccine candidate, DPX-0907, which showed that the vaccine elicited an antigen-specific immune response in the majority of ovarian cancer patients analyzed. “We are encouraged that DPX-0907 is well tolerated when administered at the 0.25-or-one-millilitre dose levels,” Dr. Marc Mansour, [...]